Manages well-differentiated thyroid cancer. Sold as Cytomel, Triostat. Every FDA application for this active ingredient: 2 branded and 10 generic.
As of Nov 15, 2026, FDA lists 12 applications for Liothyronine Sodium (sold as Cytomel, Triostat), first approved May 8, 1956, with 0 new uses approved and 0 published complete response letters.
| Liothyronine Sodium | Part D | $26.9M | -8% | 217,791 |
| Cytomel | Part D | $431K | +4% | 2,543 |
| Molar-Incisor Hypomineralization and Resin InfiltrationMolar Incisor Hypomineralization · Hanoi Medical University | Not applicable | Recruiting | Oct 14, 2026 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes · Enhanced Emirates Limited | Not applicable | Enrolling by invitation | May 6, 2026 |
| T4/T3 Therapy in HypothyroidismHypothyroidism Primary · University of Pennsylvania | Phase 2 | Not yet recruiting | Feb 20, 2026 |
| Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual DiseaseMedulloblastoma, Medulloblastoma, Childhood · Sabine Mueller, MD, PhD | Phase 1 / Phase 2 | Recruiting | Jan 16, 2026 |
| Novel Approaches to the Treatment of HypothyroidismHypothyroidism · UConn Health | Phase 2 / Phase 3 | Recruiting | Dec 12, 2024 |
| Thyroid Hormone Replacement After Radio Iodine: Value and EfficacyDifferentiated Thyroid Cancer, Thyroid Cancer · University Medical Center Groningen | — | Not yet recruiting | Oct 18, 2024 |
| Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal CancerRectal Cancer · St. James's Hospital, Ireland | Phase 3 | Not yet recruiting | Oct 24, 2023 |
| LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.Autoimmune Hypothyroidism · M. Medici | Phase 3 | Recruiting | Jan 12, 2023 |
| May 8, 1956 | CytomelNDA 10379 · New molecular entity | King Pharms | 16 | Marketed |
| Jan 25, 1982 | Liothyronine SodiumANDA 85755 | Watson Labs | 0 | Discontinued |
| Feb 3, 1982 | Liothyronine SodiumANDA 85753 | Watson Labs | 0 | Discontinued |
| Dec 31, 1991 | TriostatNDA 20105 · New dosage form | Ph Health | 2 | Discontinued |
| Aug 17, 2005 | Liothyronine SodiumANDA 76923 | Xgen Pharms | 0 | Marketed |
| Mar 20, 2009 | Liothyronine SodiumANDA 90097 | Dr Reddys Labs SA | 1 | Marketed |
| Jul 14, 2009 | Liothyronine SodiumANDA 90326 | Pharmobedient | 0 | Discontinued |
| Nov 29, 2012 | Liothyronine SodiumANDA 200295 | Sigmapharm Labs LLC | 3 | Marketed |
| Apr 20, 2016 | Liothyronine SodiumANDA 91382 | Sun Pharm | 1 | Marketed |
| Oct 26, 2018 | Liothyronine SodiumANDA 211510 | Teva Pharms USA | 1 | Marketed |
| Jan 22, 2021 | Liothyronine SodiumANDA 214803 | Zydus Lifesciences | 0 | Marketed |
| Feb 6, 2024 | Liothyronine SodiumANDA 218070 | Biocon Pharma | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Zydus Lifesciences